EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparison of the STANDARD M10 C . difficile , Xpert C . difficile , and BD MAX Cdiff assays as confirmatory tests in a two-step algorithm for diagnosing Clostridioides difficile infection

Hyunseul Choi, Minhee Kang iD, Sun Ae Yun, Hui-Jin Yu, Eunsang Suh, Tae Yeul Kim iD, Hee Jae Huh iD, Nam Yong Lee iD

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.01662-24 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Hyunseul Choi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Engineering Research Center, Smart Healthcare Research Institute, Samsung Medical Center, Seoul, South Korea. Hauptthemen laut MEDLINE: Clostridioides difficile, Clostridium Infections, Algorithms, Sensitivity and Specificity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SKKU | Samsung Medical Center, Sungkyunkwan University (SMC), Korea Health Industry Development Institute (KHIDI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current guidelines recommend a two-step algorithm rather than relying solely on a single test for diagnosing Clostridioides difficile infection. This algorithm starts with enzyme immunoassay (EIA) for detecting glutamate dehydrogenase (GDH) and toxins A/B, followed by nucleic acid amplification test (NAAT) for GDH-positive but toxin-negative cases. This study compared the performance of three commercial NAATs: the STANDARD M10 C. difficile , Xpert C. difficile , and BD MAX Cdiff assays, utilized as confirmatory testing of the two-step algorithm. Two hundred archived stool specimens, previously tested GDH-positive but toxin-negative by EIA, were analyzed in parallel with these NAATs and toxigenic culture, which served as the reference standard. Sensitivity, specificity, positive predictive value, and negative predictive value were 89.1%, 92.6%, 94.6%, and 85.2%, respectively, for the M10 assay; 95.8%, 86.4%, 91.2%, and 93.3%, respectively, for the Xpert assay; and 89.8%, 91.4%, 93.8%, and 86.0%, respectively, for the BD MAX assay. The rates of invalid results were 1.0%, 0.5%, and 1.0% for the M10, Xpert, and BD MAX assays, respectively. In conclusion, the M10 assay is a reliable diagnostic tool, performing comparably to the Xpert and BD MAX assays when used as confirmatory testing in the two-step algorithm. IMPORTANCE While numerous studies have assessed nucleic acid amplification tests (NAATs) as stand-alone tests for diagnosing Clostridioides difficile infection, limited research has compared their performance as confirmatory tests in a two-step algorithm. This study evaluated the performance of three commercial NAATs (M10, Xpert, and BD MAX assays) using 200 archived stool specimens initially tested as glutamate dehydrogenase (GDH)-positive but toxin-negative by GDH/toxin A/B enzyme immunoassay, the first step in the two-step algorithm. All three assays demonstrated high sensitivity (89.1% to 95.8%) and specificity (86.4% to 92.6%), with low rates of invalid results (≤1%). Our findings suggest that the M10 assay performs comparably to the Xpert and BD MAX assays when used as confirmatory testing in the two-step algorithm. Offering similar performance and turnaround time to these widely used assays at a slightly lower cost, the M10 assay serves as a practical alternative in this setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clostridioides difficileClostridium InfectionsAlgorithmsSensitivity and SpecificityFecesNucleic Acid Amplification TechniquesGlutamate DehydrogenaseBacterial ProteinsHumansBacterial ToxinsImmunoenzyme TechniquesEnterotoxinsMolecular Diagnostic Techniques

Stichwörter der Autor:innen

BD MAXClostridioides difficileM10Xperttwo-step algorithm

Substanzen

Glutamate DehydrogenaseBacterial ProteinsBacterial ToxinsEnterotoxins

Autor:innen und Institutionen

  • Biomedical Engineering Research Center, Smart Healthcare Research Institute, Samsung Medical Center, Seoul, South Korea.
  • Center for Clinical Medicine, Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, South Korea.
  • Department of Laboratory Medicine, Seoul Medical Center, Seoul, South Korea.
  • Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

ORCID-Profile: Minhee Kang, Tae Yeul Kim, Hee Jae Huh, Nam Yong Lee

Förderung

  • SKKU | Samsung Medical Center, Sungkyunkwan University (SMC)
  • Korea Health Industry Development Institute (KHIDI)

Zitieren

APA

Choi, H., Kang, M., Yun, S. A., Yu, H. J., Suh, E., Kim, T. Y., Huh, H. J., & Lee, N. Y. (2025). Comparison of the STANDARD M10 C . difficile , Xpert C . difficile , and BD MAX Cdiff assays as confirmatory tests in a two-step algorithm for diagnosing Clostridioides difficile infection. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01662-24

Vancouver

Choi H, Kang M, Yun SA, Yu HJ, Suh E, Kim TY, et al. Comparison of the STANDARD M10 C . difficile , Xpert C . difficile , and BD MAX Cdiff assays as confirmatory tests in a two-step algorithm for diagnosing Clostridioides difficile infection. Microbiology Spectrum. 2025. doi:10.1128/spectrum.01662-24

BibTeX
@article{Choi2025,
  author = {Choi, Hyunseul and Kang, Minhee and Yun, Sun Ae and Yu, Hui-Jin and Suh, Eunsang and Kim, Tae Yeul and Huh, Hee Jae and Lee, Nam Yong},
  title = {Comparison of the STANDARD M10 C . difficile , Xpert C . difficile , and BD MAX Cdiff assays as confirmatory tests in a two-step algorithm for diagnosing Clostridioides difficile infection},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.01662-24}
}
Kostenlos starten →